# A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Source: https://onco.cc/trials/nct06336291/  
OnCo record `nct06336291` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of L19TNF in glioma & glioblastoma, run by Philogen S.p.A., active and no longer recruiting.

## Summary

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence is a phase 2 interventional study registered as NCT06336291 by Philogen S.p.A., with 90 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-06. Interventions recorded: L19TNF and Lomustine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06336291
- Phase: 2
- Setting: A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
- Sponsor: Philogen S.p.A.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06336291: https://clinicaltrials.gov/study/NCT06336291

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [Philogen S.p.A.](https://onco.cc/companies/philogen-s-p-a/)

---
JSON: https://onco.cc/api/v1/entities/nct06336291.json